Rebiotix's RBX2660 demonstrates positive outcome in Phase II trial for C. diff. infection

Microbiome company Rebiotix has reported a positive outcome for RBX2660 from the Phase II PUNCH clinical trial for the prevention of recurrent Clostridium difficile (C. diff.) infection.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news